Answers are grounded in this paper and cite their sources.
Observational analysis supports placental growth factor as a potential diagnostic tool, highlighting improvements in maternal and perinatal outcomes for hypertensive patients.
Preeclampsia is a leading cause of maternal morbidity and adverse perinatal outcomes in Canada. Growing evidence supports the novel blood-based biomarker Placental Growth Factor (PlGF) as a diagnostic test to accelerate the timely diagnosis of preeclampsia, enhancing care for hypertensive pregnant patients. Despite national endorsement, challenges like regional disparities and test standardization hinder PlGF implementation. The Canadian PlGF Strategy & Research Consortium convened with representation from clinicians, researchers, and patient partners to discuss the current state of PlGF testing. We universally agreed there is an urgent need to implement diagnostic PlGF testing to improve maternal and perinatal outcomes in Canada.
No takes yet. Share an insight, caveat, or question.
McLaughlin et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: